Arrowsmith

What Arrowsmith does

Arrowsmith Inc. is a Japan-based, privately held biotechnology company founded in 2025 and headquartered in Ibaraki. Its stated mission is to address antimicrobial resistance (AMR), positioning the company in the global effort to develop countermeasures against drug-resistant infections. The company is in an early operational stage, with a headcount reported at 1-10 employees and no publicly disclosed products, customers, or pricing.

The company is led by a three-person founding team combining scientific, operational, and technical leadership: Hiroki Ando as Founder, CEO, and Chief Scientific Officer (CScO); Kazuyuki Sakamoto as Co-Founder and Chief Operating Officer (COO); and Shun Iwatani as Co-Founder and Chief Technology Officer (CTO). The composition suggests a science-led organization pairing wet-lab research direction (CScO) with platform/technology buildout (CTO) and operational scaling (COO). The company maintains a public web presence at arrowsmith.co.jp.

Arrowsmith has raised approximately $48.3 million across two funding rounds within roughly ten months of incorporation. The Series 1 in August 2025 was $41.8M and led by JIC Venture Growth Investments with JAFCO participating; the Series 2 in June 2026 was approximately $6.5M and broadened the syndicate to include ANRI and DBJ Capital alongside JAFCO and JIC Venture Growth Investments. The business model, revenue mechanics, product pipeline, and go-to-market strategy are not disclosed in the available input data, and represent material information gaps for any commercial assessment.

Name

Arrowsmith

Legal name

Arrowsmith Inc.

Website

https://arrowsmith.co.jp

Company type

Private

Founded year

2025

Headcount range

1–10 employees

Short description

Arrowsmith is a Japan-based biotech startup founded in 2025 that targets antimicrobial resistance, led by a three-person founder team spanning scientific, operational, and technical functions, and capitalized by approximately $48M in equity funding.

Ownership category

akta.pro rank

Product category

Biotechnology / Antimicrobial Drug Discovery

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks (HLAJAIAF)

Keywords

• Antimicrobial resistance
• Biotechnology research
• Drug discovery
• Infectious disease therapeutics
• Life sciences

Headquarters

HQ city

Ibaraki

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Arrowsmith is a Japan-based biotechnology company developing solutions aimed at combating antimicrobial resistance (AMR). The company focuses on research and development of therapeutic approaches to address drug-resistant infections, with the stated mission of creating a world free from the pain and fear of antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Daiichi Sankyo: Daiichi Sankyo is one of Japan's largest pharmaceutical companies with research programs in infectious disease and historical involvement in antimicrobial R&D. As a major Japanese incumbent, it represents a relevant comparable for scale, geography, and potential strategic engagement with focused AMR biotechs.
• Roche: Roche is a global pharmaceutical and diagnostics leader with substantial infectious disease and AMR-related diagnostics investments (e.g., cobas systems). It represents a comparable large incumbent whose combined pharma-diagnostics approach frames the strategic universe in which pure-play AMR therapeutics like Arrowsmith operate.
• Shionogi & Co. Shionogi is a major Japanese pharmaceutical company with a leading antimicrobial franchise including the recently launched cefiderocol. As a regional incumbent with deep AMR expertise and Japanese domicile, it represents the most credible local industry anchor Arrowsmith may partner with, acquire assets from, or eventually exit to.
• Pfizer: Pfizer is a global pharmaceutical leader with an active antimicrobial portfolio and a founding role in the AMR Action Fund. As a broad incumbent with explicit strategic commitment to replenishing the antibiotic pipeline, Pfizer is a meaningful benchmark for the corporate development opportunities facing AMR-focused companies like Arrowsmith.

Direct peers

• Paratek Pharmaceuticals: Paratek Pharmaceuticals (now part of Gurnet Point) developed and commercialized antibiotics including omadacycline targeting resistant pathogens. Its end-to-end AMR focus, from discovery through approval, makes it a structurally comparable peer to Arrowsmith.
• Cidara Therapeutics: Cidara Therapeutics develops antiviral and antimicrobial Cloudbreak drug-Fc conjugates targeting serious infections including influenza and AMR-related indications. Its antimicrobial platform and pipeline focus makes it a directly comparable early-stage AMR peer to Arrowsmith.
• Melinta Therapeutics: Melinta Therapeutics is a US antibiotics-focused company developing therapies for drug-resistant bacterial infections, including commercial-stage products like vabomere. It directly parallels Arrowsmith as a pure-play antimicrobial therapeutics developer serving the same AMR market.
• Iterum Therapeutics: Iterum Therapeutics is a clinical-stage US biotech developing oral and intravenous antibiotics targeting multi-drug resistant pathogens. It is a direct comparable to Arrowsmith given its singular focus on combating AMR through novel antimicrobial chemistry.
• VenatoRx Biosciences: VenatoRx Biosciences is a privately-held US biotech developing new antibiotics active against resistant Gram-negative pathogens. Its narrow focus on novel antibacterial chemistry to address AMR directly mirrors Arrowsmith's therapeutic thesis and stage profile.

Regional players

• Meiji Seika Pharma: Meiji Seika Pharma is a Japanese pharmaceutical subsidiary of Meiji Holdings with a long-standing antibiotics portfolio including carbapenems. It is comparable to Arrowsmith as a Japan-headquartered company with deep AMR focus and serves as a likely strategic peer or potential acquirer within the domestic market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrowsmith